Protocol Ledger

NCT05817903 · Phase II · RECRUITING

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Interventional Phase II clinical trial protocol NCT05817903 sponsored by Consorzio Oncotech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-18 Enrollment: 118 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05817903
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)118 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05817903
Protocol FieldVerified Registry Value
NCT IdentifierNCT05817903
Consolidated Lead SponsorConsorzio Oncotech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment118 participants (ESTIMATED)
Registered Start Date2023-04-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05817903
Hospital Research SiteLocationSite Profile
Azienda Ospedaliero Universitaria CareggiFlorence, ItalyOpen Hospital Dossier ->
Fondazione IRCCS Istituto Nazionale dei TumoriMilan, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI